Talizumab

Drug Profile

Talizumab

Alternative Names: Anti-IgE monoclonal antibody Hu 901; HU 901; TNX 901

Latest Information Update: 14 Mar 2008

Price : $50

At a glance

  • Originator Tanox
  • Class Monoclonal antibodies
  • Mechanism of Action Immunosuppressants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Peanut hypersensitivity

Most Recent Events

  • 26 Feb 2004 Genentech, Novartis and Tanox, Inc., have settled all litigation among themselves for the development and commercialisation of certain anti-IgE antibodies including Omalizumab and TNX 901
  • 26 Feb 2004 Suspended - Phase-II for Peanut allergy in USA (unspecified route)
  • 12 Mar 2003 Data from the 60th Anniversary Meeting of the American Academy of Allergy and Asthma and Immunology (AAAAI-2003) have been added to the Immunological Disorders therapeutic trials section ,
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top